Tagged with research,

Korea Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic area in South Korea. Mr Kim also reveals how Daiichi Sankyo Korea plans to embrace the company’s global strategy of expanding into the new area of oncology.  …

Spain Jesús Fernández-Pacheco Mena, country manager of hmR Spain, a health market research specialist, highlights the innovative “sell out” model of obtaining market data and the strategy in place to change the industry´s mindset to utilize this information. Furthermore, he highlights the services they provide and how this will evolve in…

USA PJ Brooks PhD, program director in the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) in the USA, highlights the importance of going beyond one disease at a time in clinical trials, some of the roadblocks that still remain…

France Professor Alexander Eggermont, general director of Gustave Roussy, gives insights into the transformation of the Hospital under his ten-year leadership mandate. He also explains the rationale behind creating Cancer Core Europe, a collaborative platform of Europe’s seven leading cancer institutes.   Our system brings between 3500 and 4000 patients into…

Korea Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical research environment over the past four years, the need to foster local CROs if the government is to truly embrace innovation, and the cultural differences in…

China Kang Wei, managing director for the R&D-based Pharmaceutical Association Committee (RDPAC) under the China Association of Enterprises with Foreign Investment, shares her priorities for RDPAC in the next few years, her members’ contribution to the Chinese healthcare environment and the national Healthy China 2030 strategy, as well as the importance…

Malaysia Click here to download the Healthcare & Life Sciences Review Malaysia 2018. After recent elections conducted in May 2018 saw Mahathir Mohamad returning as Prime Minister after 15 years to seal a historic victory, Malaysia is again back on its feet. Bolstered by well-established institutions, a fully-functional IP framework and strong…

France INCa – Institut National du Cancer (The National Cancer Institute)       The National Cancer Institute (INCa) is the state agency of health and scientific expertise in oncology in charge of coordinating actions to fight against cancer. Created by the public health law of August 9, 2004, it is placed…

Spain Andreu Mas-Colell, former minister of finance for Catalonia and president of the Barcelona Institute of Science and Technology (BIST), discusses the mission and activities of the institution as a driver of multidisciplinary research in the region. Mas-Colell also describes the condition of innovation and technology in Catalonia, highlights the region’s…

China Song Ruilin, executive president of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), discusses his association’s mandate, key achievements and the future of innovative Chinese pharmaceuticals and biotech.   Innovation is at the core of PhIRDA. Any organization that supports innovation, realizes the country’s dream of biomedical innovation and…

Turkey Sule Mene, co-founder, president and CEO of Mene Health Group, shares with PharmaBoardroom the journey of her company starting as the first government-approved CRO of Turkey, its parallel growth alongside the increasingly prominent clinical trial environment of the country, evolution to becoming a value chain group of companies in clinical…

Malaysia A map showing 18 of the active clinical trials sites in Malaysia in 2017. The sites are spread across the entire nation and cover a variety of therapeutic areas – including gastroenterology / hepatology, cardiology and oncology –  with a cluster of activity in Kuala Lumpur.   In terms of…